Evidence map›Paper›PMID 28826758›Full record

ArticleNeuroscience letters2017

β-Lactamase inhibitor, clavulanic acid, attenuates ethanol intake and increases glial glutamate transporters expression in alcohol preferring rats.

Alqassem Y Hakami, Youssef Sari

Open access · greenAbstract read
In one paragraph

Article in Neuroscience letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.1field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Influence of glutamate and GABA transport on brain excitatory/inhibitory balance.Experimental biology and medicine (Maywood, N.J.) · 2021
    Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Neuroimmune signaling in alcohol use disorder.Pharmacology, biochemistry, and behavior · 2019
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Alqassem Y HakamiDepartment of Pharmacology and Experimental Therapeutics, College of Pharmacy and Pharmaceutical Sciences, University of Toledo, Toledo, OH, USA.
Youssef SariDepartment of Pharmacology and Experimental Therapeutics, College of Pharmacy and Pharmaceutical Sciences, University of Toledo, Toledo, OH, USA. Electronic address: youssef.sari@utoledo.edu.
University of Toledo · US

Funding

Rodents with Genetic Differences in Alcohol PreferenceU24AA015512 · NIAAA · INDIANA UNIVERSITY INDIANAPOLIS · PI BELL, RICHARD LOWELL · 2015 to 2019
$2.7M
The role of GLT1 in the modulation of alcohol-drinking behavior in P rats.R01AA019458 · NIAAA · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI SARI, YOUSSEF · 2011 to 2015
$1.1M
NIAAA NIH HHS R01 AA019458NIAAA NIH HHS U24 AA015512
6 · The paper itself

Abstract

Studies from our laboratory showed that upregulation of glutamate transporter 1 (GLT-1) and cystine-glutamate exchanger (xCT) expression with ceftriaxone, β-lactam antibiotic, in the brain was associated with attenuation of ethanol consumption. In this study, we tested clavulanic acid, which is another β-lactam compound with negligible antimicrobial activity, on ethanol consumption and expression of GLT-1, xCT and glutamate aspartate transporter (GLAST) in male alcohol-preferring (P) rats. Clavulanic acid has the central β-lactam pharmacophore that is critical for the upregulation of GLT-1 and xCT expression. We found that clavulanic acid, at 5mg/kg (i.p.) dose, significantly attenuated ethanol consumption and ethanol preference in P rats as compared to vehicle-treated group. This effect was associated with a significant increase in water intake in clavulanic acid treated group. Importantly, we found that clavulanic acid increased the expression of GLT-1 and xCT in nucleus accumbens. However, there was no effect of clavulanic acid on GLAST expression in the nucleus accumbens. Clavulanic acid treatment did not upregulate the expression of GLT-1, xCT and GLAST in prefrontal cortex. These findings revealed that clavulanic acid at 20-40 fold lower dose than ceftriaxone can attenuate ethanol consumption, in part through upregulation of GLT-1 and xCT expression in the nucleus accumbens. Thus, we suggest that clavulanic acid might be used as an alternative option to ceftriaxone to attenuate ethanol drinking behavior.

Indexed as

Alcohol DrinkingAmino Acid Transport Systems, AcidicAmino Acid Transport System y+Animalsbeta-Lactamase InhibitorsClavulanic AcidDisease Models, AnimalExcitatory Amino Acid Transporter 1Excitatory Amino Acid Transporter 2MaleNucleus AccumbensPrefrontal CortexRatsAmino Acid Transport Systems, AcidicAmino Acid Transport System y+beta-Lactamase InhibitorsClavulanic AcidExcitatory Amino Acid Transporter 1Excitatory Amino Acid Transporter 2Slc1a2 protein, ratSlc1a3 protein, ratSlc7a11 protein, ratClavulanic acidEthanol dependenceGLASTGLT-1GlutamatexCT

Identifiers

PMID28826758
PMCPMC5604845
OpenAlexW2742708327

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.